The Michigan Department of Insurance and Financial Services (DIFS) wants public feedback on its plans to add coverage of opioid overdose reversal medication, and medication-assisted treatment for opioid use disorder to its health care coverage.
As part of its updating of benefits for its Essential Health Benefits (EHB) benchmark plan for the 2022 plan year, the state plans to add coverage of at least one intranasal spray opioid reversal agent to its plan. Additionally, it seeks to remove barriers to prescribing buprenorphine and other generic equivalents for the treatment of opioid use disorder.
The move comes after the Centers for Medicare and Medicaid Services offered greater flexibility to states to modify their plans.
“The Patient Protection and Affordable Care Act requires non-grandfathered plans in the individual and small group markets, both on and off the Exchange, to cover EHBs in ten categories based on the state’s EHB-benchmark plan. DIFS first selected a benchmark plan in 2012 for use in the 2014 to 2016 plan years and re-assessed its selection for plan year 2017, opting to retain a substantially similar benchmark plan to promote continuity in the individual and small group markets,” the department said.
The department is seeking public comment, as required by law, and will accept them until 5:00 p.m., April 24, 2020. Comments can be sent electronically to DIFS-EHBcomments@michigan.gov.
More information about the proposed updates to the 2022 plan are available online on the Michigan DIFS website.